AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.AbbVie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @AbbVie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

Media:

Gabby Tarbert   
(224) 244-0111
gabrielle.tarbert@abbvie.com

Investors:

Liz Shea
(847) 935-2211
liz.shea@abbvie.com

 

Cision View original content:https://www.prnewswire.com/news-releases/abbvie-to-host-full-year-and-fourth-quarter-2025-earnings-conference-call-302652211.html

SOURCE AbbVie

News Provided by PR Newswire via QuoteMedia

AbbVieABBVnyse:abbvpharmaceutical investing
ABBV
The Conversation (0)
Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

- Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at week 14 versus placebo 1 - RINVOQ is the first and only Janus Kinase (JAK) inhibitor approved to... Keep Reading...
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

- Oral presentations highlight efficacy and safety outcomes from the upadacitinib (RINVOQ ® ) clinical trial program in adults with moderately to severely active Crohn's disease, and investigational use of linaclotide (LINZESS ® ) in treating functional constipation in pediatric patients aged 6... Keep Reading...
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin... Keep Reading...
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused... Keep Reading...
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1CB2 receptors, today announced an update regarding BayMedica LLC ("BayMedica"), a wholly owned... Keep Reading...
Box of Moderna COVID-19 vaccine vials with red caps and labels.

Moderna to Pay US$950 Million to Settle COVID-19 Vaccine Patent Dispute

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine.The pharmaceuticals giant announced it has reached a global settlement with Arbutus Biopharma (NASDAQ:ABUS) and Genevant Sciences GmbH over claims... Keep Reading...
Scientists examining a sample under a microscope in a lab setting.

Gilead to Acquire Arcellx in US$7.8 Billion Bet on Cancer Therapy

Gilead Sciences (NASDAQ:GILD) announced plans to acquire cancer immunotherapy partner Arcellx (NASDAQ:ACLX) in a deal worth up to US$7.8 billion, moving to take full control of their jointly developed multiple myeloma therapy anito-cel as it seeks to expand its oncology pipeline.The agreement,... Keep Reading...
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its second quarter of... Keep Reading...
Pill labeled "GLP-1" on a $100 bill background.

As GLP-1 Brands Go Prime Time, Regulators Flag Growing Illicit Market

At Super Bowl LX, companies behind blockbuster GLP-1 medications spent tens of millions of dollars to court a mass audience. But as brand-name makers and telehealth platforms race to normalize and expand access, regulators on both sides are warning of a parallel surge in counterfeit, compounded,... Keep Reading...

Latest News

More News

Interactive Chart

Latest Press Releases

Outstanding Gold Recovery Results for Seven Leaders

Gold Mining, Processing and Cash Update

CSAMT survey completed at Mt Solitary

Allied Critical Metals Further Highlights Rapid Payback, Capital Efficiency and Infrastructure from Borralha PEA

Related News

precious metals investing

Outstanding Gold Recovery Results for Seven Leaders

precious metals investing

Gold Mining, Processing and Cash Update

base metals investing

CSAMT survey completed at Mt Solitary

Allied Critical Metals Further Highlights Rapid Payback, Capital Efficiency and Infrastructure from Borralha PEA

gold investing

Byron King: Gold, Silver, Oil/Gas — Stock Ideas and Strategy Now

gold investing

Jaime Carrasco: Gold Going "Much Higher," Silver Force Majeure Inevitable

gold investing

Garrett Goggin: Gold, Silver in New Era, My Stock Strategy Now